Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Wants More Details On Obama’s Precision Medicine Initiative

This article was originally published in The Gray Sheet

Executive Summary

The president announced a new plan before Congress that could bolster federal funding for diagnostics and personalized medicine. Industry commended the administration’s move but was also cautious due to the lack of detail and says it wants to be at the drawing table when specifics are put to paper.

You may also be interested in...



Administration Dismisses Industry Link Between Precision Medicine Initiative And Device Tax

The White House does not see a connection between President Obama’s call to increase federal funding for medical research and industry push to drop the medical device tax to funnel more money into R&D. However, the administration says it is open to discussing the tax with the new Republican Congress.

Obama Wants $215 Million Infusion For Precision Medicine

The president provided details on his administration's Precision Medicine Initiative, including funds to sequence at least a million new whole genomes and update FDA’s oversight of next-generation genome sequencing.

Lawmakers Seek Input On Dx Regs, With Lab-Developed Tests In Focus

The House Energy and Commerce Committee is seeking feedback on legislative initiatives Congress should enact in 2015 regarding regulation of diagnostics, and in particular in response to FDA's plan to regulate laboratory developed tests.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel